ZBH

+ Watchlist + Portfolio

Zimmer Biomet Holdings, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $88.06
52-Week Range: $79.12 – $106.88
Market Cap: $16.84B
P/E (TTM): 21.43
EPS (TTM): 4.12
Dividend Yield: 1.09%

Advanced Metrics

Price/Book: 1.33
PEG Ratio: 0.55
Return on Equity: 6.41%
Return on Assets: 3.88%
Gross Margin: 69.52%
Operating Margin: 17.96%
Profit Margin: 9.48%
Current Ratio: 1.69
Debt/Equity: 0.60
Total Debt: $7.60B
Free Cash Flow: $1.07B
Revenue Growth: 4.80%
Earnings Growth: 33.80%
Enterprise Value: $23.99B

ZBH Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$6.94B	$7.39B	$7.68B	$8.23B
Cost of Revenue	$2.02B	$2.08B	$2.19B	$2.49B
Gross Profit	$4.92B	$5.31B	$5.49B	$5.74B
Research & Development	$406.00M	$458.70M	$437.40M	$458.50M
Selling, General & Admin	$2.76B	$2.84B	$2.93B	$3.26B
Operating Expenses	$3.73B	$3.86B	$3.96B	$4.38B
Operating Income	$1.19B	$1.45B	$1.53B	$1.36B
EBITDA	$1.49B	$2.22B	$2.25B	$2.22B
Pretax Income	$403.50M	$1.07B	$1.04B	$830.80M
Income Tax	$112.30M	$42.20M	$131.40M	$125.70M
Net Income	$231.40M	$1.02B	$903.80M	$705.10M
Diluted EPS	1.10	4.88	4.43	3.55
Diluted Shares	210.30M	209.70M	203.90M	198.70M

ZBH Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$375.70M	$415.80M	$525.50M	$591.90M
Receivables	$1.38B	$1.44B	$1.48B	$1.70B
Inventory	$2.15B	$2.39B	$2.24B	$2.29B
Current Assets	$4.43B	$4.61B	$4.67B	$5.12B
Total Assets	$21.07B	$21.50B	$21.37B	$23.09B
Current Liabilities	$2.36B	$2.86B	$2.45B	$2.58B
Long-Term Debt	$5.15B	$4.87B	$5.34B	$6.93B
Total Debt	$5.70B	$5.77B	$6.20B	$7.52B
Total Liabilities	$9.04B	$9.01B	$8.89B	$10.39B
Retained Earnings	$9.56B	$10.38B	$11.10B	$11.61B
Shareholders' Equity	$12.02B	$12.48B	$12.47B	$12.70B
Working Capital	$2.07B	$1.75B	$2.22B	$2.54B
Net Debt	$5.32B	$5.35B	$5.68B	$6.93B

ZBH Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.28B	$1.58B	$1.50B	$1.70B
Capital Expenditure	-$217.60M	-$394.50M	-$356.80M	-$276.90M
Free Cash Flow	$1.07B	$1.19B	$1.14B	$1.42B
Depreciation & Amortisation	$926.40M	$951.70M	$996.30M	$1.09B
Stock-Based Compensation	$105.00M	$99.80M	$101.00M	$90.20M
Investing Cash Flow	-$529.20M	-$778.90M	-$888.10M	-$1.98B
Financing Cash Flow	-$843.80M	-$763.50M	-$484.50M	$326.00M
Dividends Paid	-$201.20M	-$200.90M	-$196.00M	-$190.30M
Share Repurchases	-$126.40M	-$692.20M	-$868.00M	-$487.00M
Net Change in Cash	-$88.30M	$39.20M	$126.80M	$47.40M

ZBH Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.91B	$2.08B	$2.00B	$2.24B	$2.09B	$2.18B
Cost of Revenue	$549.80M	$592.20M	$559.30M	$792.40M	$576.20M	$635.50M
Gross Profit	$1.36B	$1.49B	$1.44B	$1.45B	$1.51B	$1.54B
Research & Development	$110.60M	$113.30M	$115.90M	$118.70M	$103.40M	$104.80M
Selling, General & Admin	$758.80M	$814.80M	$811.40M	$872.30M	$849.90M	$899.30M
Operating Expenses	$1.02B	$1.09B	$1.10B	$1.17B	$1.12B	$1.17B
Operating Income	$338.90M	$396.40M	$338.30M	$282.60M	$395.10M	$374.00M
EBITDA	$549.60M	$575.70M	$638.20M	$453.90M	$640.10M	$598.80M
Pretax Income	$229.00M	$224.60M	$279.20M	$98.00M	$301.30M	$255.10M
Income Tax	$46.50M	$71.20M	$48.00M	-$39.90M	$63.00M	$55.50M
Net Income	$182.00M	$152.80M	$230.90M	$139.30M	$238.10M	$198.30M
Diluted EPS	0.91	0.77	1.16	—	1.22	1.03
Diluted Shares	199.70M	198.30M	198.80M	—	195.80M	192.80M

ZBH Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.38B	$556.90M	$1.29B	$591.90M	$424.20M	$410.00M
Receivables	$1.53B	$1.61B	$1.60B	$1.70B	$1.73B	$1.77B
Inventory	$2.24B	$2.45B	$2.48B	$2.29B	$2.25B	$2.27B
Current Assets	$5.59B	$5.05B	$5.83B	$5.12B	$4.96B	$5.10B
Total Assets	$22.18B	$22.87B	$23.49B	$23.09B	$22.72B	$22.80B
Current Liabilities	$2.29B	$2.70B	$2.40B	$2.58B	$2.86B	$3.01B
Long-Term Debt	$6.58B	$6.75B	$7.51B	$6.93B	$6.30B	$6.28B
Total Debt	$7.18B	$7.57B	$8.11B	$7.52B	$7.47B	$7.48B
Total Liabilities	$9.78B	$10.33B	$10.72B	$10.39B	$10.04B	$10.17B
Retained Earnings	$11.23B	$11.34B	$11.52B	$11.61B	$11.80B	$11.96B
Shareholders' Equity	$12.40B	$12.53B	$12.76B	$12.70B	$12.67B	$12.62B
Working Capital	$3.30B	$2.35B	$3.43B	$2.54B	$2.10B	$2.08B
Net Debt	$5.79B	$7.02B	$6.82B	$6.93B	$7.05B	$7.07B

ZBH Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$382.80M	$378.20M	$418.70M	$517.40M	$359.40M	$447.80M
Capital Expenditure	-$47.00M	-$80.10M	-$65.00M	-$84.80M	-$75.30M	-$116.40M
Free Cash Flow	$335.80M	$298.10M	$353.70M	$432.60M	$284.10M	$331.40M
Depreciation & Amortisation	$254.40M	$271.80M	$283.60M	$284.00M	$270.00M	$270.80M
Stock-Based Compensation	$19.60M	$21.20M	$25.30M	$24.10M	$24.20M	$24.60M
Investing Cash Flow	-$106.00M	-$1.38B	-$163.30M	-$322.00M	-$159.00M	-$190.80M
Financing Cash Flow	$575.40M	$163.80M	$483.80M	-$897.00M	-$369.20M	-$271.10M
Dividends Paid	-$47.80M	-$47.50M	-$47.50M	-$47.50M	-$46.90M	-$46.50M
Share Repurchases	-$229.80M	-$7.20M	$0.00	-$250.00M	-$250.10M	-$250.70M
Net Change in Cash	$852.00M	-$842.20M	$739.20M	-$701.60M	-$168.80M	-$14.20M

Market Snapshot

About

Zimmer Biomet Holdings is a global leader in musculoskeletal healthcare, specializing in the design, manufacture, and marketing of orthopedic reconstructive products, sports medicine, biologics, extremities, and trauma products. The company provides solutions for knee, hip, shoulder, elbow, foot, and ankle replacement, as well as dental implants and related surgical products. Zimmer Biomet serves healthcare professionals and patients in more than 100 countries worldwide.